Probe-hit GlaxoSmithKline announces profits slump

April 30, 2014

GlaxoSmithKline, the British drugs giant facing a series of probes into alleged staff corruption, announced sliding profits on Wednesday, one week after unveiling a group makeover.

GSK's net profits slumped 30 percent to £668 million ($1.12 billion, 811 million euros) in the first quarter compared with the first three months of 2013, the company said in an earnings statement.

Revenue fell 10 percent to £5.61 billion, while GSK said that a Chinese had impacted sales growth at the company's emerging markets division.

In a further blow, Polish prosecutors earlier this month said they had extended a probe into allegations that GlaxoSmithKline bribed doctors into promoting one of its drugs.

The company is also investigating alleged by staff at its pharmaceuticals division in Iraq.

GSK last year admitted that senior employees appeared to have breached Chinese law, after Beijing authorities alleged that staff had bribed government officials, pharmaceutical industry groups, hospitals and doctors to promote sales.

"The group takes these allegations seriously and is continuing to co-operate fully with the Chinese authorities," GSK said in Wednesday's earnings statement.

It added that it was not currently possible "to make a reliable estimate of the financial effect, if any, that could result" from the China probe.

The pharmaceutical sector's landscape has meanwhile changed dramatically over the past week, largely owing to deals struck between GlaxoSmithKline and Swiss rival Novartis—and could alter even further should US giant Pfizer succeed with a $100-billion bid for British company AstraZeneca.

A string of takeovers and ventures will see Novartis sharpen its focus on the high-grossing cancer sector, GSK boost its share in vaccines and US company Eli Lilly strengthen its animal health unit.

Also last week, Valeant Pharmaceuticals offered to acquire Botox-maker Allergan for more than $45 billion.

On Monday, Pfizer insisted that it wanted to secure a blockbuster merger with AstraZeneca that will fuel research in cancer after revealing that an informal approach worth almost $100 billion had been rejected.

The huge shake-up comes as top pharmaceutical companies are battling against patents expiring on key brands and deep cuts to government healthcare spending worldwide.

Explore further: Drug giants Pfizer, AstraZeneca in $100bn merger tussle (Update)

Related Stories

Drug giants Pfizer, AstraZeneca in $100bn merger tussle (Update)

April 28, 2014
US drugs giant Pfizer wants a blockbuster merger with British rival AstraZeneca that will fuel cancer research, revealing on Monday that an informal approach worth almost $100 billion had been rejected.

Glaxo says China drugs sales slump on bribery probe (Update)

October 23, 2013
British drugmaker GlaxoSmithKline revealed on Wednesday that pharmaceuticals and vaccines sales in China tumbled 61 percent in the third quarter, as it was rocked by a state bribery probe.

GSK brushes off China probe to post solid 2013 profits (Update)

February 5, 2014
GlaxoSmithKline's net profits jumped by a fifth in 2013 as lower taxes offset flat sales, announced on Wednesday the British drugmaker hit by a bribery probe in China.

Novartis probes corruption claims in Chinese press

September 18, 2013
Swiss pharmaceutical giant Novartis announced Tuesday it has opened an internal inquiry following Chinese press accusations of corruption at its Alcon eye care division.

Novartis reshapes business with GSK, Lilly deals (Update)

April 22, 2014
Swiss pharmaceutical firm Novartis AG launched a major overhaul of its business Tuesday, unveiling a series of multibillion-dollar deals with Britain's GlaxoSmithKline PLC and the U.S.'s Eli Lilly & Co. that heralds more ...

GSK says lifts Indian pharmaceutical unit stake to 75%

March 10, 2014
GlaxoSmithKline has lifted its stake in the group's Indian subsidiary to 75 percent, the British drugmaker said on Monday.

Recommended for you

In most surgery patients, length of opioid prescription, number of refills spell highest risk for misuse

January 17, 2018
The possible link between physicians' opioid prescription patterns and subsequent abuse has occupied the attention of a nation in the throes of an opioid crisis looking for ways to stem what experts have dubbed an epidemic. ...

Patients receive most opioids at the doctor's office, not the ER

January 16, 2018
Around the country, state legislatures and hospitals have tightened emergency room prescribing guidelines for opioids to curb the addiction epidemic, but a new USC study shows that approach diverts attention from the main ...

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.